List of Excipients in Branded Drug NORPACE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	NORPACE	disopyramide phosphate	0025-2752	FD&C RED NO. 3
Pfizer Laboratories Div Pfizer Inc	NORPACE	disopyramide phosphate	0025-2752	FD&C YELLOW NO. 6
Pfizer Laboratories Div Pfizer Inc	NORPACE	disopyramide phosphate	0025-2752	GELATIN
Pfizer Laboratories Div Pfizer Inc	NORPACE	disopyramide phosphate	0025-2752	LACTOSE

Norpace Excipient Strategy and Commercial Opportunities for Disopyramide

Last updated: October 9, 2026

Norpace is an established disopyramide phosphate product with limited active patent protection and a concentrated competitive field. The strongest commercial opportunities are generic immediate-release capsules, controlled-release capsules, hospital and specialty-pharmacy supply, and differentiated formulations that improve swallowing, dosing flexibility, or supply reliability. Excipient selection must account for disopyramide’s narrow therapeutic margin, anticholinergic adverse effects, and the need for reproducible dissolution.

What is Norpace and which formulations are commercially relevant?

Norpace contains disopyramide phosphate, a Class 1A antiarrhythmic approved for the treatment of documented ventricular arrhythmias. The product has been marketed in immediate-release and controlled-release oral capsules. Norpace is an older small-molecule product, so the commercial opportunity is primarily generic and lifecycle-based rather than based on new chemical entity exclusivity.

Attribute	Norpace
Active ingredient	Disopyramide phosphate
Therapeutic class	Class 1A antiarrhythmic
Dosage forms	Immediate-release capsules; controlled-release capsules
Historical strengths	100 mg and 150 mg immediate-release; 150 mg controlled-release
FDA regulatory pathway for competitors	ANDA for pharmaceutical equivalents; 505(b)(2) for materially differentiated products
Primary commercial users	Cardiologists, electrophysiologists, hospitals, specialty pharmacies
Key development risk	Dose-related toxicity and formulation-driven exposure variability
Main market opportunity	Reliable generic supply and controlled-release competition

Disopyramide is used less broadly than newer antiarrhythmics. Its use persists in selected ventricular arrhythmia cases and in some specialty cardiac practices. The limited prescriber base reduces total market size but can support attractive economics when the number of reliable suppliers is small.

What excipients are used in Norpace capsules?

The Norpace immediate-release capsule is generally described as containing disopyramide phosphate with conventional solid oral excipients, including lactose, corn starch, magnesium stearate, and capsule-shell materials. Capsule shells typically contain gelatin and titanium dioxide, with colorants varying by strength and manufacturer labeling. The controlled-release product uses a multiparticulate or matrix-based release system and requires a different excipient strategy from the immediate-release capsule.

The exact inactive-ingredient profile should be established from the applicable FDA-approved labeling and reference-product samples before development. DailyMed and FDA labeling identify the marketed product composition, but inactive ingredients can differ between legacy brand presentations and current authorized generic or generic products.[1]

Functional role of the principal excipients

Excipient class	Commercial function	Relevance to disopyramide
Lactose or alternative filler	Provides capsule fill mass and improves blend uniformity	Requires assessment for lactose intolerance labeling and moisture control
Corn starch or pregelatinized starch	Supports bulk, disintegration, and powder flow	Can alter disintegration if concentration or grade changes
Magnesium stearate	Lubrication during capsule filling or powder processing	Excessive levels can slow wetting and dissolution
Colloidal silicon dioxide	Improves flow and reduces cohesion	Useful when low-dose drug loading creates segregation risk
Crospovidone or croscarmellose sodium	Accelerates disintegration	May be unnecessary in a conventional, rapidly dissolving capsule
Hypromellose, ethylcellulose, or methacrylate polymers	Controls release in extended-release systems	Determines the dissolution profile and food sensitivity
Povidone or hypromellose	Binder or coating aid	Supports pellet strength and coating uniformity
Talc	Anti-tacking agent in coating systems	Relevant to controlled-release pellet manufacture
Gelatin or hypromellose	Capsule shell	Hypromellose shells support vegetarian and certain religious-market positioning

What excipient strategy is appropriate for generic Norpace?

The most defensible immediate-release strategy is a simple, low-risk capsule formulation that closely reproduces the reference product’s dissolution behavior without unnecessary excipient complexity.

A typical development platform would include:

1. Disopyramide phosphate as the active pharmaceutical ingredient.
2. Lactose monohydrate or a compatible alternative filler.
3. Corn starch or pregelatinized starch for disintegration and bulk.
4. Magnesium stearate at a controlled, low concentration.
5. Colloidal silicon dioxide if needed to improve flow.
6. Hard gelatin or hypromellose capsule shells.

The formulation should prioritize blend uniformity, capsule-fill consistency, rapid and robust dissolution, and low sensitivity to lubricant mixing time. A low-excipient-count formulation reduces supply-chain exposure and simplifies scale-up.

When should a developer avoid direct excipient substitution?

Substitution is commercially attractive only when it does not create bioequivalence or labeling risk. Higher-risk substitutions include:

• Replacing lactose with a high-viscosity polymer or large quantity of insoluble filler.
• Increasing magnesium stearate to correct flow problems.
• Using a superdisintegrant concentration that produces an atypical early dissolution spike.
• Changing capsule-shell composition without confirming dissolution and stability performance.
• Adding surfactants that materially increase apparent solubility or alter food-effect behavior.

For an ANDA, excipients do not need to be identical to those in the reference listed drug, but the proposed product must meet pharmaceutical equivalence, bioequivalence, quality, and labeling requirements. FDA’s inactive-ingredient database can support excipient selection, but prior use in another product does not eliminate product-specific safety and compatibility testing.[2]

What formulation patents protect Norpace?

Norpace is an older marketed product, and the commercial protection associated with the original disopyramide product is largely historical. The key patent position is unlikely to be a blocking composition-of-matter issue for a modern generic developer. Relevant rights would instead involve:

• Legacy controlled-release delivery technology.
• Specific pellet, matrix, or coating systems.
• Manufacturing processes.
• Narrow method-of-use claims.
• Product-specific improvements owned by later manufacturers.

The FDA Orange Book is the controlling source for patents and regulatory exclusivity listed against an approved drug product. A current diligence review should distinguish patents listed for the reference product from unlisted patents, expired patents, and patents covering a competitor’s distinct formulation.[3]

How many patents cover Norpace?

The commercial risk is more likely to arise from formulation execution than from a broad active-ingredient patent. Disopyramide phosphate is an established active ingredient, and the original product’s core exclusivity period has expired. Any remaining Orange Book-listed patent must be evaluated by product, dosage form, patent expiration date, and statutory use code.

For a conventional immediate-release generic capsule, the expected patent risk is low relative to a new controlled-release formulation. A controlled-release product may encounter formulation or method patents even when the active ingredient is no longer protected.

When does Norpace lose exclusivity?

Norpace’s original small-molecule exclusivity has expired. The product is therefore eligible for generic competition subject to FDA approval, bioequivalence, manufacturing capacity, and any remaining listed patent or regulatory exclusivity.

Exclusivity category	Norpace status
New chemical entity exclusivity	Expired
Original composition-of-matter protection	Expired or commercially irrelevant
Current commercial protection	Primarily regulatory, manufacturing, supply, and formulation-based
Biosimilar exclusivity	Not applicable
Immediate-release generic pathway	ANDA
Differentiated controlled-release pathway	ANDA if pharmaceutically equivalent; otherwise potentially 505(b)(2)

A generic applicant must evaluate Paragraph I, II, III, or IV certifications for any patents listed in the Orange Book. If no relevant unexpired patent remains listed for the target presentation, Paragraph IV litigation risk may be limited. If an unexpired patent is listed, a Paragraph IV certification can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.[4]

What Paragraph IV and litigation risks exist for Norpace?

The principal Paragraph IV risk would attach to a controlled-release or otherwise differentiated product, not to the basic disopyramide molecule. Litigation exposure depends on:

• Whether the reference product has an unexpired listed patent.
• Whether the proposed product practices the patent claims.
• The strength of written-description, enablement, obviousness, and infringement defenses.
• The commercial value of the target market.
• The availability of an alternative immediate-release launch.

A generic company can reduce exposure by developing an immediate-release product first, then pursuing controlled release after confirming the patent and regulatory position. A formulation that uses a materially different release mechanism can support non-infringement arguments, but it may increase bioequivalence and clinical-development complexity.

No biosimilar challenge applies because Norpace is a chemically synthesized small molecule, not a biologic. FDA’s biosimilar pathway is therefore irrelevant to disopyramide competition.[5]

What controlled-release excipient systems are commercially attractive?

Controlled-release disopyramide is the higher-value formulation opportunity because it can support fewer daily doses, smoother exposure, and differentiation from immediate-release capsules. It also carries greater technical and regulatory risk.

Multiparticulate pellet system

A pellet approach can use:

• Drug-layered starter cores.
• Povidone or hypromellose binder.
• Ethylcellulose or methacrylate polymer release coating.
• Talc or colloidal silicon dioxide as coating aids.
• Capsule filling of coated pellets with a hard-shell capsule.

Advantages include flexible release control, reduced dose dumping risk, and the ability to tune coating weight gain. Risks include pellet-size variation, coating defects, batch-to-batch dissolution drift, and manufacturing cost.

Hydrophilic matrix system

A matrix capsule can use hypromellose or another hydrophilic polymer to slow drug release. It has a simpler manufacturing process than coated pellets but may show greater sensitivity to tablet or granule structure, polymer grade, agitation conditions, and food intake.

Lipid or hydrophobic matrix

A hydrophobic matrix can control water penetration and drug diffusion. It may reduce manufacturing cost but can produce more complex dissolution behavior and greater risk of incomplete release or food-dependent exposure.

For disopyramide, a multiparticulate system is generally the stronger commercial platform where the goal is robust release control and lower dose-dumping risk. The final selection must be driven by dissolution similarity, pharmacokinetic performance, stability, and manufacturing economics.

What FDA regulatory status applies to Norpace generics?

Immediate-release generic capsules are generally pursued through an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. Controlled-release products require more extensive characterization, including:

• Comparative dissolution across multiple media and pH conditions.
• Alcohol dose-dumping assessment where relevant.
• Fed and fasted pharmacokinetic studies.
• In vitro-in vivo correlation analysis where useful.
• Stability under ICH conditions.
• Evaluation of capsule fill uniformity and release-control attributes.

Disopyramide’s safety profile makes exposure control important. Excessive peak concentrations can increase cardiac and anticholinergic toxicity, while inadequate exposure can reduce antiarrhythmic effectiveness. FDA’s guidance on bioequivalence for modified-release products is therefore central to development planning.[6]

What generic launch scenarios exist for Norpace?

Launch scenario	Probability of technical success	Commercial profile
Immediate-release 100 mg capsule	High	Lower development cost; price competition likely
Immediate-release 150 mg capsule	High	Broadest generic opportunity
Controlled-release 150 mg capsule	Moderate	Greater differentiation and margin potential
Authorized generic or contract-manufactured product	High	Fastest route if supply and commercial partner are available
Sprinkle or modified capsule	Low to moderate	Requires new performance and labeling support
Pediatric liquid formulation	Low	Limited demand; stability and taste challenges
Hospital unit-dose packaging	High	Supply-chain and procurement differentiation
Dual-source specialty supply	High	Attractive if incumbents have shortages or limited capacity

The most practical entry model is an immediate-release ANDA supported by a reliable API source and a second-stage controlled-release program. A company can improve margins through contract supply, hospital purchasing agreements, specialty-pharmacy distribution, and multi-strength packaging rather than through extensive reformulation.

What commercial opportunities exist for Norpace excipients and manufacturing?

Excipient suppliers can target three needs.

First, direct generic replication requires reliable pharmaceutical-grade lactose, starch, lubricants, capsule shells, and flow aids. The opportunity is stable but price-sensitive.

Second, controlled-release development requires polymer systems, coating equipment, multiparticulate manufacturing, and analytical support. This segment has higher switching costs and stronger technical differentiation.

Third, supply assurance is commercially important. A manufacturer that can qualify dual sources for disopyramide API, capsule shells, and release-controlling polymers can reduce shortage risk and secure institutional contracts.

Manufacturing barriers include:

• API particle-size and polymorph control.
• Powder segregation during capsule filling.
• Moisture sensitivity of excipients and capsule shells.
• Reproducibility of coating weight gain.
• Dissolution drift during scale-up.
• Stability of the active ingredient in polymer-coated systems.
• Validation of cleaning and cross-contamination controls.

Geographic opportunities are strongest in the United States, Canada, Europe, Japan, and selected emerging markets with established antiarrhythmic use and limited local competition. U.S. market entry has the clearest ANDA framework, while Europe may require decentralized or centralized regulatory strategy depending on the product and reference-member-state position.

How strong is the Norpace patent estate?

The patent estate is weak for the active ingredient and conventional immediate-release capsule. It is stronger only where a competitor has obtained rights covering a specific controlled-release architecture, manufacturing process, or narrow use.

Patent area	Estimated commercial risk
Disopyramide active ingredient	Low
Conventional immediate-release capsule	Low
Controlled-release formulation	Moderate
Manufacturing process	Low to moderate
Method of use	Low to moderate
Unlisted third-party formulation patent	Product-specific
Biosimilar exclusivity	None

Patent strength should be assessed claim-by-claim. A patent with narrow coating-composition claims may be easy to design around but difficult to invalidate economically. A broader controlled-release claim may create greater launch risk but is more vulnerable to prior-art challenges for an older product.

What revenue exposure and competitive landscape should investors assess?

Norpace is unlikely to represent a large primary-care pharmaceutical market. Revenue exposure is concentrated in a small number of prescribers and patients, which creates both risk and opportunity.

The commercial case improves when:

• The product has limited generic competition.
• One or more suppliers experience manufacturing disruption.
• Hospitals require a dependable source.
• Controlled-release competition is absent.
• The manufacturer has an established cardiovascular sales channel.
• API and capsule manufacturing are vertically integrated.

The commercial case weakens when multiple ANDA holders compete on price, the reference product has low prescription volume, or prescribers shift patients to alternative antiarrhythmics. A launch forecast should therefore use unit volume, average selling price, competitor count, wholesaler inventory, and hospital contract penetration rather than relying on historical brand revenue alone.

Key Takeaways

• Norpace contains disopyramide phosphate and is an established small-molecule antiarrhythmic product.
• Original active-ingredient exclusivity has expired; the main barriers are regulatory execution, formulation know-how, manufacturing reliability, and supply access.
• Immediate-release capsules offer the lowest-risk generic opportunity.
• Controlled-release capsules offer greater differentiation but require more demanding dissolution and pharmacokinetic development.
• A conventional excipient platform can use lactose or an alternative filler, starch, magnesium stearate, flow aid, and gelatin or hypromellose capsules.
• Excipient changes must preserve dissolution, bioequivalence, stability, and capsule-fill uniformity.
• Paragraph IV exposure is primarily relevant to any unexpired formulation or method patent covering controlled release.
• Biosimilar competition does not apply.
• Commercial value is concentrated in reliable supply, hospital procurement, specialty distribution, and differentiated release profiles.
• The strongest launch strategy is usually immediate-release entry followed by a controlled-release or supply-differentiated product.

FAQs

Can a generic company use different excipients from Norpace?

Yes. FDA permits excipient differences when the proposed product meets applicable safety, quality, pharmaceutical-equivalence, and bioequivalence requirements. The substitution must not create a material change in performance or labeling.

Is lactose-free disopyramide commercially feasible?

Yes, but the developer must replace lactose without impairing blend uniformity, capsule-fill weight, dissolution, or stability. Microcrystalline cellulose, mannitol, or pregelatinized starch may be considered, subject to formulation and regulatory testing.

Is Norpace a narrow-therapeutic-index drug?

Disopyramide has a narrow clinical safety margin in practice because excessive exposure can produce cardiac conduction effects, anticholinergic toxicity, and other adverse reactions. Formulation changes should therefore be evaluated with tight exposure and dissolution controls.

Can disopyramide be developed as an oral liquid?

A liquid could address swallowing limitations, but it would require taste masking, chemical and microbiological stability, preservative evaluation, dosing-device validation, and a suitable regulatory bridge. The market is narrower than for capsules.

Does a controlled-release Norpace product require a new clinical trial?

It requires product-specific bioequivalence and performance evidence. The required studies depend on whether the proposed product is pharmaceutically equivalent to the reference controlled-release product or is sufficiently different to require a 505(b)(2) application.

References

1. National Library of Medicine. (n.d.). DailyMed: Norpace and disopyramide phosphate prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, 45th edition. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2019). Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. U.S. Department of Health and Human Services.